Poziotinib Induces Responses in EGFR Exon 20+ NSCLC

home / oncclub / poziotinib-induces-responses-in-egfr-exon-20-nsclc

Yasir Y. Elamin, MD, discusses findings from a phase 2 study (NCT03066206), which found that poziotinib induced an investigator-assessed overall response rate of 32% in patients with non–small cell lung cancer harboring EGFR exon 20 mutations.

Yasir Y. Elamin, MD

Poziotinib Elicits Encouraging Responses in EGFR Exon 20–Mutated NSCLC

August 2nd 2022

Poziotinib produced an encouraging overall response rate in patients with non–small cell lung cancer harboring EGFR exon 20 mutations, meeting the primary end point in cohort 1 of a phase 2 trial.

Yasir Y. Elamin, MD

Poziotinib Elicits Encouraging, Insertion Location–Specific Response Rates in EGFR Exon 20–Mutant NSCLC

August 4th 2022

Yasir Y. Elamin, MD, explained the rationale, design, and key findings of a phase 2 study evaluating poziotinib in patients with EGFR exon 20–mutated non–small cell lung cancer.

Yasir Y. Elamin, MD

Dr. Elamin on Poziotinib Efficacy and Mutation Insertion Location in NSCLC

August 11th 2022

Yasir Y. Elamin, MD, discusses the efficacy of poziotinib in patients with EGFR exon 20–mutated non–small cell lung cancer with near-loop vs far-loop mutations.

Elamin Elaborates on Poziotinib in EGFR Exon 20–Mutant NSCLC

Elamin Elaborates on Poziotinib in EGFR Exon 20–Mutant NSCLC

September 12th 2022

Dr Elamin discusses results from a phase 2 study of poziotinib efficacy in EGFR exon 20–mutant non–small cell lung cancer and highlights the agent’s sensitivity in relation to insertion location.